Abstract: The present invention relates to method of therapy selection for patient suffering from glioblastoma. Using in vitro and in vivo approaches, the inventors demonstrated the critical role of CD90 in GBM migration/invasion. They showed that CD90 signaling though SRC, FAK and RhoA promotes cell migration and importantly, that high CD90 expression impacts on the cell response to the SRC inhibitor dasatinib. In particular, the present invention relates to a method for predicting whether a subject will be eligible to a treatment with a drug selected from the group consisting of SRC inhibitor, FAK inhibitor or RhoA inhibitor by determining the expression level of CD90 in a sample obtained from the subject.
Type:
Grant
Filed:
May 9, 2018
Date of Patent:
October 11, 2022
Assignees:
INSERM (INSTITUT NAITONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE), UNIVERSITÉ DE RENNES I, CENTRE EUGENE MARQUIS, ENIOS APPLICATIONS PRIVATE LIMITED COMPANY
Inventors:
Eric Chevet, Tony Avril, Aristotelis Chatziioannou
Abstract: The present invention relates to a method for detecting the interaction in a cell between a RNA and a protein, wherein the cell expresses: —the RNA fused to a hairpin, called hairpin-tagged RNA, —the protein fused to a tag, called tagged-protein, —a reporter protein fused to a protein which binds to said hairpin, wherein said reporter protein is a luminescent reporter protein, said method comprises the lysis of the cell and the detection of the complex tagged protein/hairpin-tagged RNA/hairpin binding protein—reporter protein.
Type:
Application
Filed:
September 9, 2019
Publication date:
August 12, 2021
Applicants:
Centre National de la Recherche Scientifique, Institut Naitonal de la Sante et de la Recherche Medicale, Institut Curie
Abstract: The invention relates to an ex vivo method for expanding monocytes, macrophages or dendritic cells, which method comprises inhibiting the expression or the activity of MafB and c-Maf in monocytes, macrophages or dendritic cells; and expanding the cells in the presence of at least one cytokine or an agonist of cytokine receptor signaling.
Type:
Grant
Filed:
January 10, 2008
Date of Patent:
April 8, 2014
Assignee:
INSERM (Institut Naitonal de la Sante et de la Recherche Medicale)